Transcriptional responses to loss or gain of function of the leucine-rich repeat kinase 2 (LRRK2) gene uncover biological processes modulated by LRRK2 activity

Human Molecular Genetics

Volumn 21, Issue 1, 2012, Pages 163-174

  Nikonova, Elena V ^a,c   Xiong, Yulan ^b   Tanis, Keith Q ^a   Dawson, Valina L ^b   Vogel, Robert L ^a   Finney, Eva M ^a   Stone, David J ^a   Reynolds, Ian J ^a   Kern, Jonathan T ^a   Dawson, Ted M ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; LEUCINE RICH REPEAT KINASE 2; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CELL ORGANELLE; CONTROLLED STUDY; CORPUS STRIATUM; DOWN REGULATION; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; GAIN OF FUNCTION MUTATION; GENE MUTATION; KIDNEY; LOSS OF FUNCTION MUTATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE PHOSPHORYLATION; PARKINSON DISEASE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ANIMALS; BRAIN; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; TRANSCRIPTION, GENETIC;

EID: 83455206098     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddr451     Document Type: Article

References (52)

1. Lees, A.J., Hardy, J. and Revesz, T. (2009) Parkinson's disease. Lancet, 373, 2055-2066.
2. Moore, D.J., West, A.B., Dawson, V.L. and Dawson, T.M. (2005) Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci., 28, 57-87.
3. Paisan-Ruiz, C., Jain, S., Evans, E.W., Gilks, W.P., Simon, J., van der Brug, M., Lopez de Munain, A., Aparicio, S., Gil, A.M., Khan, N. et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron, 44, 595-600.
4. Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R.J., Calne, D.B. et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron, 44, 601-607.
5. Mata, I.F., Wedemeyer, W.J., Farrer, M.J., Taylor, J.P. and Gallo, K.A. (2006) LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci., 29, 286-293.
6. Cookson, M.R. (2010) The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat. Rev. Neurosci., 11, 791-797.
7. Giasson, B.I., Covy, J.P., Bonini, N.M., Hurtig, H.I., Farrer, M.J., Trojanowski, J.Q. and Van Deerlin, V.M. (2006) Biochemical and pathological characterization of Lrrk2. Ann. Neurol., 59, 315-322.
8. Gilks, W.P., Abou-Sleiman, P.M., Gandhi, S., Jain, S., Singleton, A., Lees, A.J., Shaw, K., Bhatia, K.P., Bonifati, V., Quinn, N.P. et al. (2005) A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet, 365, 415-416.
9. Biskup, S. and West, A.B. (2009) Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease. Biochim. Biophys. Acta, 1792, 625-633.
10. Kamikawaji, S., Ito, G. and Iwatsubo, T. (2009) Identification of the autophosphorylation sites of LRRK2. Biochemistry, 48, 10963-10975.
11. Greggio, E., Jain, S., Kingsbury, A., Bandopadhyay, R., Lewis, P., Kaganovich, A., van der Brug, M.P., Beilina, A., Blackinton, J., Thomas, K.J. et al. (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis., 23, 329-341.
12. Greggio, E., Taymans, J.M., Zhen, E.Y., Ryder, J., Vancraenenbroeck, R., Beilina, A., Sun, P., Deng, J., Jaffe, H., Baekelandt, V. et al. (2009) The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites. Biochem. Biophys. Res. Commun., 389, 449-454.
13. Pungaliya, P.P., Bai, Y., Lipinski, K., Anand, V.S., Sen, S., Brown, E.L., Bates, B., Reinhart, P.H., West, A.B., Hirst, W.D. et al. (2010) Identification and characterization of a leucine-rich repeat kinase 2 (LRRK2) consensus phosphorylation motif. PLoS One, 5, e13672.
14. Greggio, E., Zambrano, I., Kaganovich, A., Beilina, A., Taymans, J.M., Daniels, V., Lewis, P., Jain, S., Ding, J., Syed, A. et al. (2008) The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J. Biol. Chem., 283, 16906-16914.
15. Imai, Y., Gehrke, S., Wang, H.Q., Takahashi, R., Hasegawa, K., Oota, E. and Lu, B. (2008) Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J., 27, 2432-2443.
16. Jaleel, M., Nichols, R.J., Deak, M., Campbell, D.G., Gillardon, F., Knebel, A. and Alessi, D.R. (2007) LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem. J., 405, 307-317.
17. Smith, W.W., Pei, Z., Jiang, H., Dawson, V.L., Dawson, T.M. and Ross, C.A. (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci., 9, 1231-1233.
18. West, A.B., Moore, D.J., Biskup, S., Bugayenko, A., Smith, W.W., Ross, C.A., Dawson, V.L. and Dawson, T.M. (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl Acad. Sci. USA, 102, 16842-16847.
19. West, A.B., Moore, D.J., Choi, C., Andrabi, S.A., Li, X., Dikeman, D., Biskup, S., Zhang, Z., Lim, K.L., Dawson, V.L. et al. (2007) Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet., 16, 223-232.
20. Li, X., Moore, D.J., Xiong, Y., Dawson, T.M. and Dawson, V.L. (2010) Reevaluation of phosphorylation sites in the Parkinson disease-associated leucine-rich repeat kinase 2. J. Biol. Chem., 285, 29569-29576.
21. Sen, S., Webber, P.J. and West, A.B. (2009) Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization. J. Biol. Chem., 284, 36346-36356.
22. Lewis, P.A., Greggio, E., Beilina, A., Jain, S., Baker, A. and Cookson, M.R. (2007) The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem. Biophys. Res. Commun., 357, 668-671.
23. Xiong, Y., Coombes, C.E., Kilaru, A., Li, X., Gitler, A.D., Bowers, W.J., Dawson, V.L., Dawson, T.M. and Moore, D.J. (2010) GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet., 6, e1000902.
24. Li, X., Tan, Y.C., Poulose, S., Olanow, C.W., Huang, X.Y. and Yue, Z. (2007) Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J. Neurochem., 103, 238-247.
25. Ito, G., Okai, T., Fujino, G., Takeda, K., Ichijo, H., Katada, T. and Iwatsubo, T. (2007) GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry, 46, 1380-1388.
26. Liu, M., Dobson, B., Glicksman, M.A., Yue, Z. and Stein, R.L. (2010) Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities. Biochemistry, 49, 2008-2017.
27. Liu, Z., Wang, X., Yu, Y., Li, X., Wang, T., Jiang, H., Ren, Q., Jiao, Y., Sawa, A., Moran, T. et al. (2008) A Drosophila model for LRRK2-linked parkinsonism. Proc. Natl Acad. Sci. USA, 105, 2693-2698.
28. Ng, C.H., Mok, S.Z., Koh, C., Ouyang, X., Fivaz, M.L., Tan, E.K., Dawson, V.L., Dawson, T.M., Yu, F. and Lim, K.L. (2009) Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. J. Neurosci., 29, 11257-11262.
29. Andres-Mateos, E., Mejias, R., Sasaki, M., Li, X., Lin, B.M., Biskup, S., Zhang, L., Banerjee, R., Thomas, B., Yang, L. et al. (2009) Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). J. Neurosci., 29, 15846-15850.
30. Lee, S.B., Kim, W., Lee, S. and Chung, J. (2007) Loss of LRRK2/PARK8 induces degeneration of dopaminergic neurons in Drosophila. Biochem. Biophys. Res. Commun., 358, 534-539.
31. Wang, D., Tang, B., Zhao, G., Pan, Q., Xia, K., Bodmer, R. and Zhang, Z. (2008) Dispensable role of Drosophila ortholog of LRRK2 kinase activity in survival of dopaminergic neurons. Mol. Neurodegener., 3, 3.
32. Sakaguchi-Nakashima, A., Meir, J.Y., Jin, Y., Matsumoto, K. and Hisamoto, N. (2007) LRK-1, a C. elegans PARK8-related kinase, regulates axonal-dendritic polarity of SV proteins. Curr. Biol., 17, 592-598.
33. Yao, C., El Khoury, R., Wang, W., Byrd, T.A., Pehek, E.A., Thacker, C., Zhu, X., Smith, M.A., Wilson-Delfosse, A.L. and Chen, S.G. (2010) LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease. Neurobiol. Dis., 40, 73-81.
34. Tong, Y., Yamaguchi, H., Giaime, E., Boyle, S., Kopan, R., Kelleher, R.J. 3rd and Shen, J. (2010) Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc. Natl Acad. Sci. USA, 107, 9879-9884.
35. Li, Y., Liu, W., Oo, T.F., Wang, L., Tang, Y., Jackson-Lewis, V., Zhou, C., Geghman, K., Bogdanov, M., Przedborski, S. et al. (2009) Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat. Neurosci., 12, 826-828.
36. Tong, Y., Pisani, A., Martella, G., Karouani, M., Yamaguchi, H., Pothos, E.N. and Shen, J. (2009) R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc. Natl Acad. Sci. USA, 106, 14622-14627.
37. Li, X., Patel, J.C., Wang, J., Avshalumov, M.V., Nicholson, C., Buxbaum, J.D., Elder, G.A., Rice, M.E. and Yue, Z. (2010) Enhanced striataldopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J. Neurosci., 30, 1788-1797.
38. Ramonet, D., Daher, J.P., Lin, B.M., Stafa, K., Kim, J., Banerjee, R., Westerlund, M., Pletnikova, O., Glauser, L., Yang, L. et al. (2011) Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One, 6, e18568.
39. Dawson, T.M., Ko, H.S. and Dawson, V.L. (2010) Genetic animal models of Parkinson's disease. Neuron, 66, 646-661.
40. Berwick, D.C. and Harvey, K. (2011) LRRK2 signaling pathways: the key to unlocking neurodegeneration? Trends Cell. Biol., 21, 257-265.
41. Winrow, C.J., Tanis, K.Q., Reiss, D.R., Rigby, A.M., Uslaner, J.M., Uebele, V.N., Doran, S.M., Fox, S.V., Garson, S.L., Gotter, A.L. et al. (2010) Orexin receptor antagonism prevents transcriptional and behavioral plasticity resulting from stimulant exposure. Neuropharmacology, 58, 185-194.
42. Tain, L.S., Mortiboys, H., Tao, R.N., Ziviani, E., Bandmann, O. and Whitworth, A.J. (2009) Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat. Neurosci., 12, 1129-1135.
43. Kumar, A., Greggio, E., Beilina, A., Kaganovich, A., Chan, D., Taymans, J.M., Wolozin, B. and Cookson, M.R. (2010) The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation. PLoS One, 5, e8730.
44. Gehrke, S., Imai, Y., Sokol, N. and Lu, B. (2010) Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature, 466, 637-641.
45. Biskup, S., Moore, D.J., Celsi, F., Higashi, S., West, A.B., Andrabi, S.A., Kurkinen, K., Yu, S.W., Savitt, J.M., Waldvogel, H.J. et al. (2006) Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann. Neurol., 60, 557-569.
46. Hatano, T., Kubo, S., Imai, S., Maeda, M., Ishikawa, K., Mizuno, Y. and Hattori, N. (2007) Leucine-rich repeat kinase 2 associates with lipid rafts. Hum. Mol. Genet., 16, 678-690.
47. Piccoli, G., Condliffe, S.B., Bauer, M., Giesert, F., Boldt, K., De Astis, S., Meixner, A., Sarioglu, H., Vogt-Weisenhorn, D.M., Wurst, W. et al. (2011) LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. J. Neurosci., 31, 2225-2237.
48. Shin, N., Jeong, H., Kwon, J., Heo, H.Y., Kwon, J.J., Yun, H.J., Kim, C.H., Han, B.S., Tong, Y., Shen, J. et al. (2008) LRRK2 regulates synaptic vesicle endocytosis. Exp. Cell. Res., 314, 2055-2065.
49. Saha, S., Guillily, M.D., Ferree, A., Lanceta, J., Chan, D., Ghosh, J., Hsu, C.H., Segal, L., Raghavan, K., Matsumoto, K. et al. (2009) LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J. Neurosci., 29, 9210-9218.
50. Liu, B.H., Wang, X., Ma, Y.X. and Wang, S. (2004) CMV enhancer/human PDGF-beta promoter for neuron-specific transgene expression. Gene Ther., 11, 52-60.
51. Irizarry, R.A., Hobbs, B., Collin, F., Beazer-Barclay, Y.D., Antonellis, K.J., Scherf, U. and Speed, T.P. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics, 4, 249-264.
52. Livak, K.J. and Schmittgen, T.D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) method. Methods, 25, 402-408.